Psychotic Disorders - United Kingdom

Revenue in the Psychotic Disorders market is projected to reach US$218.50m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 1.03%, resulting in a market volume of US$230.00m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$215.90 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in United Kingdom is experiencing significant growth and development.

Customer preferences: Customers in the United Kingdom are increasingly seeking effective treatments for psychotic disorders. They are looking for medications that can effectively manage symptoms and improve their quality of life. Additionally, there is a growing demand for personalized treatment options that take into account individual patient needs and preferences. Customers are also becoming more aware of the importance of early diagnosis and intervention, leading to an increased demand for diagnostic tools and services.

Trends in the market: One of the key trends in the Psychotic Disorders market in United Kingdom is the growing adoption of innovative treatment options. Pharmaceutical companies are investing in research and development to bring new and improved medications to the market. These medications aim to target specific symptoms and provide better outcomes for patients. Additionally, there is a growing focus on the development of non-pharmacological interventions, such as cognitive behavioral therapy, to complement medication-based treatments.Another trend in the market is the increasing use of digital health technologies. Mobile applications and online platforms are being used to provide support and resources to individuals with psychotic disorders. These technologies allow for remote monitoring of symptoms, access to educational materials, and peer support networks. They also enable healthcare providers to deliver virtual care and telemedicine services, improving access to care for individuals in remote or underserved areas.

Local special circumstances: The United Kingdom has a well-established healthcare system, which provides access to comprehensive mental health services. The National Health Service (NHS) plays a central role in the provision of care for individuals with psychotic disorders. The NHS offers a range of services, including diagnosis, treatment, and support. This ensures that individuals with psychotic disorders have access to the care they need, regardless of their financial situation.

Underlying macroeconomic factors: The growth and development of the Psychotic Disorders market in United Kingdom can be attributed to several macroeconomic factors. Firstly, there is an increasing prevalence of psychotic disorders in the population. This can be attributed to factors such as urbanization, stress, and lifestyle changes. As the number of individuals with psychotic disorders continues to rise, there is a growing need for effective treatments and support services.Secondly, there is a growing recognition of the economic burden associated with psychotic disorders. The costs associated with hospitalizations, medications, and lost productivity are significant. As a result, there is a greater focus on investing in the development of innovative treatments and interventions that can reduce the burden of psychotic disorders on individuals, families, and society as a whole.In conclusion, the Psychotic Disorders market in United Kingdom is experiencing growth and development due to increasing customer preferences for effective treatments, the adoption of innovative treatment options, the use of digital health technologies, the presence of a well-established healthcare system, and underlying macroeconomic factors such as the increasing prevalence of psychotic disorders and the economic burden associated with them.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.